Open AccessBrief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study
Author(s) -
Jean van Wyk,
Mounir AitKhaled,
Jesús Santos,
Stefan Scholten,
Michael Wohlfeiler,
F. Ajana,
Bryn Jones,
Maria Clara Nascimento,
Allan R. Tenorio,
Don Smith,
Jonathan Wright,
Brian Wynne
Publication year - 2021
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002655
Subject(s) - medicine , dolutegravir , lamivudine , tenofovir alafenamide , metabolic syndrome , abacavir , regimen , odds ratio , insulin resistance , gastroenterology , endocrinology , insulin , obesity , viral load , human immunodeficiency virus (hiv) , hepatitis b virus , immunology , virus , antiretroviral therapy
In TANGO, switching to dolutegravir/lamivudine was noninferior at 48 weeks to continuing 3-/4-drug tenofovir alafenamide-based regimens in virologically suppressed individuals with HIV-1. Antiretroviral agents have been associated with weight gain and metabolic complications.